莱斯康制药

LXRX NASDAQ
6.04
+0.14
+2.37%
盘后: 6.04 0 0.00% 16:05 06/18 EDT
开盘
5.95
昨收
5.90
最高
6.15
最低
5.91
成交量
32.74万
成交均量(3M)
61.72万
52周最高
13.97
52周最低
4.250
换手率
0.30%
市值
6.42亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供莱斯康制药 LXRX股票价格,莱斯康制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
展开 >

最近浏览

名称
价格
涨跌幅